Wellbutrin XL for Dysthymic Disorder

ClinicalTrials.gov ID: NCT00225251

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT00225251. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:51 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Double-Blind Treatment of Outpatients With Dysthymic Disorder With Wellbutrin XL

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a ten-week, double-blind study of Wellbutrin XL in outpatients with dysthymic disorder, a form of low-grade chronic depression. We hypothesize that patients taking Wellbutrin XL will show greater improvement in depression symptoms and psychosocial functioning than patients taking placebo.

Study identification

NCT ID: NCT00225251
Recruitment status: Completed
Study type: Interventional
Phase: Phase 4
Lead sponsor: St. Luke's-Roosevelt Hospital Center; Other
Enrollment: 18 participants

Conditions and interventions

Conditions

Dysthymic Disorder

Interventions

bupropion XL Drug
Placebo Other

Drug · Other

Eligibility (public fields only)

Age range: 18 Years to 65 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Nov 2004 (Type not available)
Primary completion: May 2008 (Actual)
Completion: Jun 2008 (Actual)
Last update posted: Nov 26, 2015

2004 – 2008

United States locations

U.S. sites: 1
U.S. states: 1
U.S. cities: 1

Facility	City	State	ZIP	Site status
Mood Disorders Research Program, St. Luke's-Roosevelt Hospital Center	New York	New York	10019	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00225251, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Nov 26, 2015 · Synced Nov 15, 2026